Type 2 diabetes is one of the most common long-term health conditions in the world. Over time, high blood sugar can damage many parts of the body, including the kidneys. When the kidneys are affected, the condition is called diabetic kidney disease.
This can become very serious, as the kidneys slowly lose their ability to filter waste from the blood. For many people, this can lead to kidney failure, which may require dialysis or a kidney transplant.
People who have both type 2 diabetes and kidney disease face very high health risks. They are more likely to have heart attacks, strokes, and other serious problems. In many cases, their life expectancy is also reduced. Because of this, doctors and researchers have been working for many years to find better treatments that can protect both the kidneys and the heart.
Now, a new study from Stanford University has brought encouraging news. The research found that a drug called canagliflozin can significantly reduce the risk of kidney failure and other serious complications in people with type 2 diabetes and kidney disease.
The study was large and carefully designed. It included 4,401 participants from 34 different countries. All of the participants were already receiving the best standard treatment for kidney disease, known as RAAS therapy. This treatment has been the main approach for nearly two decades, but it does not fully stop the disease from getting worse.
To test the new drug, researchers divided the participants into two groups. One group was given canagliflozin, while the other group received a placebo, which is a pill without any active ingredients. This allowed the scientists to clearly compare the effects of the drug.
The results were very promising. People who took canagliflozin had a 30 percent lower risk of developing kidney failure or dying from kidney or heart-related causes compared to those who took the placebo.
When looking only at kidney failure or death caused by kidney problems, the risk was reduced by 34 percent. In addition, the risk of being hospitalized for heart failure or dying from heart disease dropped by 31 percent.
These findings are important because they show that canagliflozin does more than just control blood sugar. It also provides strong protection for both the kidneys and the heart, which are two of the most vulnerable organs in people with diabetes.
Canagliflozin works in a simple but effective way. It helps the body remove extra sugar through urine. By lowering blood sugar levels, it reduces the strain on the body’s systems.
The drug already has approval from the U.S. Food and Drug Administration to treat type 2 diabetes and to lower the risk of major heart problems in people who already have heart disease.
This new research adds another important benefit. It shows that the drug can also slow down the progression of kidney disease. This is a major step forward because treatment options for diabetic kidney disease have changed very little over the past 20 years.
For patients, this could mean a better quality of life and a lower chance of needing dialysis or a transplant in the future. It also means fewer hospital visits and a lower risk of life-threatening complications.
In conclusion, canagliflozin offers a new and powerful way to protect people with type 2 diabetes from serious kidney and heart problems. While it is not a cure, it provides hope for better long-term outcomes.
As always, patients should talk to their doctors to see if this treatment is right for them. With the right care and early action, many people can live longer and healthier lives despite having diabetes.
If you care about diabetes, please read studies about diabetes and vitamin B12, and the right diet for people with type 2 diabetes.
For more health information, please see recent studies about how to eat smart with diabetes, and turmeric and vitamin D: a duo for blood pressure control in diabetic patients.
Copyright © 2026 Knowridge Science Report. All rights reserved.
